

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification : Not classified	A2	(11) International Publication Number: WO 99/30548 (43) International Publication Date: 24 June 1999 (24.06.99)
(21) International Application Number: PCT/DK99/00210 (22) International Filing Date: 14 April 1999 (14.04.99) (71) Applicant (for all designated States except US): H. LUNDBECK A/S [DK/DK]; Ottiliavej 9, DK-2500 Valby Copenhagen (DK). (72) Inventor; and (75) Inventor/Applicant (for US only): PETERSEN, Hans [-DK]; Guldagervej 11, DK-2720 Vanløse (DK). (74) Common Representative: H. LUNDBECK A/S; PETERSEN, John, Meidahl, Patent Dept., Ottiliavej 9, DK-2500 Valby Copenhagen (DK).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Upon the request of the applicant, before the expiration of the time limit referred to in Article 21(2)(a). Without international search report and to be republished upon receipt of that report. Without classification; title and abstract not checked by the International Searching Authority.</i>
(54) Title: METHOD FOR THE PREPARATION OF CITALOPRAM (57) Abstract A method for the preparation of citalopram comprising reductive hydrolysis of a compound of Formula (IV) wherein R is a N,N-disubstituted amid group or an optionally substituted 4,5-dihydro-1,3-oxazol-2-yl group, and conversion of the resulting 5-formyl compound to citalopram.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Method for the Preparation of Citalopram

The present invention relates to a method for the preparation of the well known anti-depressant drug citalopram, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile.

Background of the Invention.

Citalopram is a well known antidepressant drug that has now been on the market for some years and has the following structure:




Formula I

It is a selective, centrally acting serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitor, accordingly having antidepressant activities. The antidepressant activity of the compound has been reported in several publications, eg. J. Hyttel, *Prog. Neuro-Psychopharmacol. & Biol. Psychiat.*, **1982**, 6, 277-295 and A. Gravem, *Acta Psychiatr. Scand.*, **1987**, 75, 478-486. The compound has further been disclosed to show effects in the treatment of dementia and cerebrovascular disorders, EP-A 474580.

Citalopram was first disclosed in DE 2,657,271 corresponding to US 4,136,193. This patent publication describes the preparation of citalopram by one method and outlines a further method which may be used for preparing citalopram.

According to the process described, the corresponding 1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile is reacted with 3-(N,N-dimethylamino)propyl-chloride in the presence of methylsulfinylmethide as condensing agent. The starting material was prepared from the corresponding 5-bromo derivative by reaction with cuprous cyanide.


According to the method, which is only outlined in general terms, citalopram may be obtained by ring closure of the compound:



Formula II

in the presence of a dehydrating agent and subsequent exchange of the 5-bromo group with cuprous cyanide. The starting material of Formula II is obtained from 5-bromophthalide by two successive Grignard reactions, i.e. with 4-fluorophenyl magnesium chloride and N,N-dimethylaminopropyl magnesium chloride, respectively.

A new and surprising method and an intermediate for the preparation of citalopram were described in US Patent No 4,650,884 according to which an intermediate of the formula



Formula III

is subjected to a ring closure reaction by dehydration with strong sulfuric acid in order to obtain citalopram. The intermediate of Formula III was prepared from 5-cyanophthalide by two successive Grignard reactions, i.e. with 4-fluorophenyl magnesium halogenide and N,N-dimethylaminopropyl magnesium halogenide, respectively.


Further processes are disclosed in International patent application Nos. WO 98019511, WO 98019512 and WO 98019513. WO 98019512 and WO 98019513 relate to methods wherein a 5-amino-, 5-carboxy- or 5-(sec. aminocarbonyl)phthalide is subjected to two successive Grignard reactions, ring closure and conversion of the resulting 1,3-dihydroisobenzofuran derivative to the corresponding 5-cyano compound, i.e. citalopram. International patent application No. WO 98019511 discloses a process for the manufacture of citalopram wherein a (4-substituted-2-hydroxymethylphenyl)-(4-fluorophenyl)methanol compound is subjected to ring closure and the resulting 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofuran converted to the corresponding 5-cyano derivative which is alkylated with a (3-dimethylamino)propylhalogenide in order to obtain citalopram.

Finally, methods of preparing the individual enantiomers of citalopram are disclosed in US Patent No 4,943,590 from which it also appears that the ring closure of the intermediate of Formula III may be carried out via a labile ester with a base.

- 5 It has now, surprisingly, been found that citalopram may be manufactured by a novel favourable and safe procedure using convenient starting materials.


Summary of the invention

- 10 Accordingly, the present invention relates to a novel method for the preparation of citalopram comprising the steps of :
- a) subjecting a compound of Formula IV




Formula IV

- 15 wherein R is




- a group $\begin{matrix} \text{R2} \\ | \\ \text{N} \\ | \\ \text{R1} \end{matrix} \text{C=O}$ wherein R1 and R2 are independently selected from lower alkyl, aryl and heteroaryl, or R1 and R2 are linked and together designate a 4- or 5-membered chain optionally comprising an S, O or N atom, or
 - 4,5-dihydro-1,3-oxazol-2-yl optionally substituted in the 4- and/or 5-position with one ore more lower alkyl, aryl or heteroaryl groups
- 20 to reductive hydrolysis, and

- b) converting the resulting 5-formyl compound of Formula V



Formula V

to the corresponding 5-cyano compound, i.e. citalopram



Formula I

which is isolated as the base or a pharmaceutically acceptable salt thereof.

In another aspect, the present invention provides the novel intermediate of Formula V.

A further aspect of the invention relates to the novel intermediate for preparation of citalopram having Formula IV

In a further aspect the invention relates to the above process in which the compound of Formula IV is the S-enantiomer.

In yet another aspect, the present invention relates to an antidepressant pharmaceutical composition comprising citalopram manufactured by the process of the invention.

Throughout the specification and claims, lower alkyl refers to a branched or unbranched alkyl group having from one to six carbon atoms inclusive, such as methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl, 2,2-dimethyl-1-ethyl and 2-methyl-1-propyl.

The term aryl refers to a mono- or bicyclic carbocyclic aromatic group, such as phenyl and naphthyl, in particular phenyl.

The term heteroaryl refers to a mono- or bicyclic heterocyclic aromatic group, such as indolyl, thienyl, pyrimidyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, benzofuranyl, benzothienyl, pyridyl, and furanyl, in particular pyrimidyl, indolyl, and thienyl.

- 5 Halogen means fluoro, chloro, bromo or iodo.


Reductive hydrolysis means reduction of the group R followed by treatment with H_2O thereby forming an aldehyde group.

- 10 When R1 and R2 are linked and together designate a 4- or 5-membered chain optionally comprising an S, O or N atom, R1 and R2 together with the N-atom to which they are linked form a 5- or 6-membered ring optionally having a heteroatom selected from O, S and N in addition to the N-atom to which R1 and R2 are linked. Examples of such groups are morpholinyl, piperidyl, etc.

15

In a preferred embodiment of the invention, R is morpholinocarbonyl, di(lower alkyl)aminocarbonyl or 4,4-di(lower alkyl)-1,3-oxazolidin-2-yl, most preferably morpholinocarbonyl, dimethylaminocarbonyl or 4,4-dimethyl-1,3-oxazolidin-2-yl.

- 20 In a preferred embodiment of the invention the intermediate of Formula IV is prepared by ring closure of the corresponding compound of Formula VI:



Formula VI

- 25 Preferably the compound of Formula VI is obtained from the corresponding 5-R-substituted phthalide derivative by two successive Grignard reactions, i.e. with a Grignard reagent of 4-halogen-fluorophenyl and a Grignard reagent of 3-halogen-N,N-dimethyl-propylamine, respectively. When R is an optionally substituted 4,5-dihydro-1,3-oxazol-2-yl group the compound of Formula VI may alternatively be prepared from 4-dimethylamino-1-(4-
- 30 fluorophenyl)-butan-1-one by Grignard reaction with a properly protected 2-(hydroxymethyl)-4-(4,5-dihydro-1,3-oxazol-2-yl)-phenyl magnesium halogenide derivative.

The reductive hydrolysis of the compound of Formula IV is conveniently carried out by reduction of a compound of Formula IV with a suitable reducing agent such as an aluminium or boron containing agent, conveniently Dibal-H, superhydride, LiAlH_4 , BH_4^- (Li^+ , Na^+ or K^+), etc., followed by addition of H_2O . When R is a 4,5-dihydro-1,3-oxazol-2-yl-group the reaction may be carried out by alkylation with a proper alkylation agent, such as MeI, a dialkylsulfate or like, followed by reduction and hydrolysis as above. In all cases the reduction is performed under strictly controlled conditions, preferably at about 0°C .

10 The conversion of the 5-formyl compound of Formula V to citalopram is carried out by conversion of the formyl group to an oxime or similar group by reaction with a reagent $\text{R}_3\text{-X-NH}_2$, wherein R_3 is hydrogen, lower alkyl, aryl or heteroaryl and X is O, N or S, followed by dehydration with a common dehydrating agent, for example thionylchloride, acetic anhydride/pyridine, pyridine/HCl or phosphor pentachloride. Preferred reagents $\text{R}_3\text{-X-NH}_2$,
15 are hydroxylamin and compounds wherein R_3 is alkyl or aryl and X is N or O.

Ring closure of the compound of Formula VI may be effected by an acid or via a labile ester with a base. Acidic ring closure is performed by an inorganic acid, such as a sulfuric or phosphoric acid, or an organic acid, such as methylsulfonic, p-toluenesulfonic or trifluoroacetic acid. The basic ring closure is performed via a labile ester, such as the methane
20 sulfonyl, p-toluene sulfonyl, 10-camphorsulfonyl, trifluoroacetyl or trifluoromethanesulfonyl ester with addition of a base, such as triethyl amine, dimethylaniline, pyridine, etc. The reaction is performed in an inert solvent, preferably with cooling, in particular about 0°C and is preferably carried out by a one-pot procedure, i.e. with esterification and simultaneous
25 addition of the base. Before further reaction the intermediate of Formula VI may be separated into its enantiomers, thereby obtaining the enantiomer giving S-citalopram.

Grignard reagents of 4-halogen-fluorophenyl that may be used in the preparation of a compound of Formula VI are the magnesium halogenides, such as the chloride, bromide or
30 iodide. Preferably the magnesium bromide is used. Grignard reagents of 3-halogen-N,N-dimethylpropylamine that may be used are the magnesium halogenides, such as the chloride, bromide or iodide, preferably the magnesium chloride. Preferably the two reactions are performed successively without isolation of the intermediate.

35 Other reaction conditions, solvents, etc. are conventional conditions for such reactions and may easily be determined by a person skilled in the art.

The 5-R-substituted phthalide starting materials used in the Grignard reactions may be prepared from 5-chlorocarbonylphthalide by reaction with the proper amine compounds.

5-chlorocarbonylphthalide may again be prepared from 5-carboxyphtalide by reaction with thionyl chloride. 5-carboxyphtalide is commercially available and may be prepared by well known procedures (Tirouflet, J.; Bull.Soc.Sci. Bretagne 26, 1959,35).

The compound of general Formula I may be used as the free base or as a pharmaceutically acceptable acid addition salt thereof. As acid addition salts, such salts formed with organic or inorganic acids may be used. Exemplary of such organic salts are those with maleic, fumaric, benzoic, ascorbic, succinic, oxalic, bismethylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzene sulfonic and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromotheophylline. Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids.

The acid addition salts of the compounds may be prepared by methods known in the art. The base is reacted with either the calculated amount of acid in a water miscible solvent, such as acetone or ethanol, with subsequent isolation of the salt by concentration and cooling, or with an excess of the acid in a water immiscible solvent, such as ethylether, ethylacetate or dichloromethane, with the salt separating spontaneously.

The pharmaceutical compositions of the invention may be administered in any suitable way and in any suitable form, for example orally in the form of tablets, capsules, powders or syrups, or parenterally in the form of usual sterile solutions for injection.

The pharmaceutical formulations of the invention may be prepared by conventional methods in the art. For example, tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conventional tableting machine. Examples of adjuvants or diluents comprise: Corn starch, potato starch, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvant or additive colourings, aroma, preservatives etc. may be used provided that they are compatible with the active ingredients.

Solutions for injections may be prepared by solving the active ingredient and possible additives in a part of the solvent for injection, preferably sterile water, adjusting the solution to the desired volume, sterilisation of the solution and filling in suitable ampoules or vials.

Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, etc.

Examples

- 5 The invention is further illustrated by the following examples.

Example 1

5-(4-morpholylcarbonyl)phthalid.

- A solution of 5-chlorocarbonylphthalid (39 g, 0.2 mole) in THF (400 ml) is added to a
10 solution of morpholine (22 g, 0.25 mole) and triethylamine (26 g, 0.25 mole) in THF (200 ml) at 0 °C. The mixture is stirred for 1 hour and is allowed to warm to room temperature. The reaction mixture is then poured into ice water (500 ml). THF is evaporated off *in vacuo* and the pH of the solution is adjusted to pH=2. The solution is cooled to 5 °C and the precipitated crystals are filtered off and washed with water (100 ml).
15 Yield 38.0 g, 78%. DSC onset: 83 °C and 107 °C . Purity: 99.6% (hplc, peak area). ¹H NMR (DMSO-d₆, 250 MHz): 3.2-3.7 (8H, m), 5.45 (2H, s), 7.60 (1H, d, J=7.5 Hz), 7.72 (1H, s), 7.92 (1H, d, J=7.5 Hz). ¹³C NMR (DMSO-d₆, 62.9 MHz): 42.1, 47.7, 66.1, 70.0, 121.6, 125.3, 125.7, 127.7, 141.2, 147.7, 168.0, 170.1.
Anal. calcd. for C₁₃H₁₃O₄N₁; C, 63.15; H, 5.30; N, 5.66. Found C, 62.94; H, 5.52; N, 5.53.

Example 2

5-(N,N-dimethylcarbamyl)phthalid.

- A solution of 5-chlorocarbonylphthalid (32 g, 0.16 mole) in THF (300 ml) is added to dimethylamine (40% v/v in water, 300 ml) and ice (100 g). The mixture is stirred for 1 hour.
25 THF is evaporated off *in vacuo* and precipitated crystals are filtered off at 5 °C and washed with water (100 ml).
Yield 30.0 g, 90%. DSC onset: 154 °C . ¹H NMR (DMSO-d₆, 250 MHz): 2.9 (3H, s), 3.03 (3H, s), 5.45 (2H, s), 7.57 (1H, d, J=7.5 Hz), 7.70 (1H, s), 7.90 (1H, d, J=7.5 Hz). ¹³C NMR (DMSO-d₆, 62.9 MHz): 34.7, 40.0, 70.0, 121.4, 125.1, 125.5, 127.6, 142.1, 147.6, 169.0,
30 170.1.
Anal. calcd. for C₁₁H₁₁O₃N₁; C, 64.38; H, 5.40; N, 6.83. Found C, 64.17; H, 5.44; N, 6.61.

Example 3

5-(1-Hydroxy-2-methylprop-2-yl)carbamylphthalid.

- 35 Method A): A solution of 5-chlorocarbonylphthalid (39 g, 0.2 mole) in THF (400 ml) is added to a solution of 2-amino-2-methylpropan-1-ol (22.3 g, 0.25 mole) and triethyl-amine (26 g, 0.25 mole) in THF (200 ml) at 0 °C. The mixture is stirred for 1 hour and is allowed to warm to room temperature. The reaction mixture is then poured into ice water (500 ml). THF is evaporated off *in vacuo* and the pH of the solution is adjusted to pH=2. The solution is

cooled to 5 °C and left over night. The precipitated crystals are filtered off and washed with cold water (100 ml).

Yield 34.0 g, 68%. DSC onset: 165 °C . Purity: 99.7% (hplc, peak area). ¹H NMR (DMSO-d₆, 250 MHz): 1.33 (6H, s), 3.54 (2H, s), 5.47 (2H, s), 7.84 (1H,s), 7.90 (1H, d, J=7.5 Hz), 7.97 (1H, d, J=7.5 Hz), 8.03 (1H, s). ¹³C NMR (DMSO-d₆, 62.9 MHz): 23.6, 55.4, 67.2, 70.1, 122.1, 124.8, 126.7, 128.3, 141.2, 147.3, 165.8, 170.2.

Anal. calcd. for C₁₃H₁₅O₄N₁; C, 62.64; H, 6.07; N, 5.62. Found C, 62.37; H, 6.13; N, 5.53.

Method B): 5-Ethoxycarbonylphthalid (82 g, 0.4 mole) is added to a solution of 2-amino-2-methylpropan-1-ol (44.6 g, 0.5 mole) in toluene (100 ml). The mixture is heated to reflux temperature for 24 hours. Upon cooling the title compound is filtered off and recrystallised from hot toluene.

Yield 85.0 g, 85%. Purity: 95.0% (hplc, peak area).

Example 4

5-(4-morpholylcarbonyl)-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran, oxalate.

A solution of 4-fluorophenylmagnesium bromide, prepared from 4-fluorobromobenzene (31 g, 0.17 mole) and magnesium turnings (6 g, 0.24 mole) in dry THF (100 ml), is added dropwise to a suspension of 5-(4-morpholylcarbonyl)phthalid (36 g, 0.15 mole) in dry THF (150 ml). The temperature is kept below 5 °C. After the addition is complete, the reaction mixture is stirred for 1.5 hours at room temperature.

A second Grignard solution prepared from 3-dimethylaminopropyl chloride (22.3 g, 0.17 mole) and magnesium turnings (6 g, 0.24 mole) in dry THF (150 ml) is added to the reaction mixture. The temperature is kept below 10°C during the addition. The reaction is left overnight at room temperature with stirring.

The reaction mixture is poured into ice water (300 ml) and a saturated solution of ammonium chloride (100 ml). THF is evaporated off *in vacuo*. Dichloromethane (300 ml) is added and the organic phase is separated and washed with water (2x100 ml) and brine (50 ml). The organic phase is extracted with 2 M HCl (2x100 ml). To the aqueous phase 4 M NaOH (100 ml) is added to give a final pH of 9 or higher. The water layer is extracted with DCM (400 ml) and the organic phase is washed with water (100 ml), brine (50 ml) and dried with MgSO₄ (20 g).

Triethylamine (20 g, 0.2 mole) is added to the organic phase and the solution is cooled to 5°C. Methanesulfonyl chloride (12 g, 0.11 mole) in DCM (100 ml) is added dropwise and after addition the reaction mixture is left for one hour with stirring. The reaction mixture is washed with 0.1 M NaOH (2x100 ml) and the organic phase is dried (MgSO₄, 10 g) and the solvent is evaporated *in vacuo*. The thus obtained material is dissolved in acetone (100 ml)

and treated with anhydrous oxalic acid (13.5 g, 0.15 mole) dissolved in acetone (100 ml). The mixture is left at room temperature overnight and the precipitated oxalate is filtered off.

Yield: 19 g, 26 %. DSC onset 166 C. ¹H NMR (DMSO-d₆, 250 MHz): 1.35-1.63 (2H, m), 2.20 (2H, t, J=10 Hz), 2.64 (6H, s), 2.97 (2H, t, J=10 Hz), 3.3-3.7 (8H, m), 5.13 (1H, d, J=12.5 Hz), 5.23 (1H, d, J=12.5 Hz), 7.15 (2H, t, J=8.5 Hz), 7.32 (2H, s+d, J=1.2 Hz), 7.52-7.65 (3H, t+d, J=8.5 Hz J=1.2 Hz).

Anal. calcd. for C₂₄H₂₉N₁F₁O₃. 1.1 C₂H₂O₄; C, 61.52; H, 6.15; N, 5.48. Found C, 61.53; H, 6.22; N, 5.40.

Example 5

5-(N,N-dimethylcarbamyl)-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran, oxalate.

A solution of 4-fluorophenylmagnesium bromide, prepared from 4-fluorobromobenzene (16.5 g, 0.09 mole) and magnesium turnings (3 g, 0.12 mole) in dry THF (50 ml), is added dropwise to a suspension of 5-N,N-dimethylcarbamylphthalid (16.5 g, 0.08 mole) in dry THF (50 ml). The temperature is kept below 5 °C. After the addition is complete, the reaction mixture is stirred for 1.5 hours at room temperature.

A second Grignard solution prepared from 3-dimethylaminopropyl chloride (12 g, 0.09 mole) and magnesium turnings (3 g, 0.12 mole) in dry THF (50 ml) is added to the reaction mixture. The temperature is kept below 10° C during the addition. The reaction is 2 hours at room temperature with stirring.

The reaction mixture is poured into ice water (100 ml) and a saturated solution of ammonium chloride (50 ml). THF is evaporated off *in vacuo*. Dichloromethane (100 ml) is added and the organic phase is separated and washed with water (2x50 ml) and brine (50 ml). The organic phase is extracted with 2 M HCl (2x100 ml). To the aqueous phase is added 4 M NaOH (100 ml) to give a final pH of 9 or higher. The water layer is extracted with dichloromethane (200 ml) and the organic phase is washed with water (50 ml), brine (50 ml) and dried with MgSO₄ (20 g). dichloromethane is evaporated off *in vacuo*. To the thus obtained material is added DCM (250 ml) and triethylamine (20 g, 0.2 mole). The solution is cooled to 5° C. Methanesulfonyl chloride (18 g, 0.16 mole) is added dropwise and after addition the reaction mixture is left for one hour with stirring. The reaction mixture is washed with 0.1 M NaOH (2x100 ml) and the organic phase is dried (MgSO₄, 10 g) and the solvent is evaporated *in vacuo*. Yield: 16.5 g, 69%. ¹H NMR (DMSO-d₆, 250 MHz): 1.35-1.58 (2H, m), 2.23 (2H, t, J=8 Hz), 2.50 (6H, s), 2.83 (2H, t, J=8 Hz), 2.89 (3H, s), 2.97 (3H, s), 5.13 (1H, d, J=12.5 Hz), 5.21 (1H, d, J=12.5 Hz), 7.17 (2H, t, J=8.5 Hz), 7.30-7.38 (2H, s+d, J=7.5 Hz), 7.54- 7.66 (3H, dd+d, J=8.5 Hz J=6 Hz J=7.5 Hz).

The oxalate salt is precipitated from acetone.

Example 6

5-Formyl-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran.

The amide of Example 4 (0.025 mole) is dissolved in toluene (100 ml). The solution is cooled to 0 °C. Dibal-H (30 ml, 1M solution in toluene, 0.03 mole) is added dropwise while the temperature is kept at 0 °C. Cooling is removed and the solution is stirred for an additional 2 hours. Ice water (5 g) is added carefully and left with stirring for 30 min. K₂CO₃ (20 g) is added and stirring is continued for 10 min. The suspension is filtered and the organic phase is washed with water (30 ml). Toluene is evaporated off *in vacuo* and the title compound (free base form) is left as a clear oil. Yield: 7 g, 88%.

The oxalate salt is formed from acetone: DSC onset: 128 °C. ¹H NMR (DMSO-d₆, 250 MHz): 1.35-1.65 (2H, m), 2.24 (2H, t, J=8 Hz), 2.66 (6H, s), 3.02 (2H, t, J=8 Hz), 5.18 (1H, d, J=13 Hz), 5.28 (1H, d, J=13 Hz), 7.17 (2H, t, J=8.5 Hz), 7.60 (2H, dd, J=8.5 Hz J=6 Hz), 7.75 (1H, d, J=7.5 Hz), 7.82 (1H, s), 7.88 (1H, d, J=7.5 Hz).

Anal. calcd. for C₂₀H₂₂N₁F₁O₂ · 1.2 C₂H₂O₄; C, 61.79; H, 5.65; N, 3.22. Found C, 61.62; H, 5.86; N, 3.45.

Example 7

5-Formyl-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran oxime.

5-Formyl-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran (33 g, 0.1 mole) is dissolved in EtOH (150 ml). Hydroxylamine, HCl (14 g, 0.2 mole) in water (150 ml) is added and pH is adjusted to pH =10 using NaOH (28% aq). The mixture left with stirring for 14 hours. EtOH is removed *in vacuo* and EtOAc (200 ml) and water (100 ml) is added and the phases are separated. Evaporation of the solvents from the organic phase leaves the oxime as an oil. Yield: 33 g. 96%.

¹H NMR (DMSO-d₆, 250 MHz): 1.15-1.43 (2H, m), 2.02 (6H, s), 2.15 (4H, t+t, J=7 Hz), 5.10 (1H, d, J=12.5 Hz), 5.18 (1H, d, J=12.5 Hz), 7.10-7.30 (4H, m), 7.50-7.63 (3H, m), 8.19 (1H, s), 11.34 (1H, s).

The oxalate of the title compound is crystallized from acetone. DSC: reaction onset. ¹H NMR (DMSO-d₆, 250 MHz): 1.36-1.63 (2H, m), 2.20 (2H, t, J=8 Hz), 2.65 (6H, s), 3.00 (2H, t, J=8 Hz), 5.11 (1H, d, J=12.5 Hz), 5.21 (1H, d, J=12.5 Hz), 7.16 (2H, t, J=8.5 Hz), 7.45-7.63 (5H, m), 8.15 (1H, s) 9.35-10.05 (2H, broad peak).

Anal. calcd. for C₂₀H₂₃N₂O₂F₁ · 1.05 C₂H₂O₄; C, 60.75; H, 5.79; N, 6.41. Found C, 60.55; H, 6.06; N, 5.93.

Example 8

1-(3-Dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile, and the oxalate salt thereof.


- Method A): 5-Formyl-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofurane oxime, or oxalate salt, (12 g) is dissolved in acetic acid anhydride (20 ml) and pyridine (80ml). The solution is heated to reflux temperature for 2 hours. The volatile materials are evaporated off *in vacuo* and the remains coevaporated with toluene (2x100 ml). The thus obtained material is dissolved in acetone and oxalic acid (5 g) is added. The solution is left at 0 °C for 14 hours. Filtration yields the title compound as the hydrogen oxalate salt. Yield: 9.6 g. 66%. DSC onset: 155 °C.
- Method B): 5-Formyl-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofurane oxime, oxalate salt (1.0 g) is suspended in toluene (10 ml). SOCl₂ (2 ml) is added and the mixture is heated at reflux temperature for 15 min. Evaporation of the volatile solvents *in vacuo* leaves an oil. The oil is taken up in toluene (10 ml) and is washed with 2 N NaOH (5 ml, aq) and water (5 ml). Evaporation of the the toluene phase leaves the title compound (free base) as an oil. Yield = 0.62 g. 83% , Purity: >98.0% (hplc, peak area).

CLAIMS

1. A method for the preparation of citalopram comprising the steps of :


a) subjecting a compound of Formula IV

5




Formula IV

wherein R is



- a group $\begin{matrix} R2 \\ | \\ N \\ | \\ R1 \end{matrix} \begin{matrix} O \\ || \\ C \end{matrix}$ wherein R1 and R2 are independently selected from lower alkyl, aryl and heteroaryl or R1 and R2 are linked and together designate a 4- or 5-membered chain optionally comprising an S, O or N atom,
 - 4,5-dihydro-1,3-oxazol-2-yl optionally substituted in the 4- and or 5-position with one or more lower alkyl, aryl or heteroaryl groups
- to reductive hydrolysis, and


15 b) converting the resulting 5-formyl compound of Formula V



Formula V

to the corresponding 5-cyano compound, citalopram

20



Formula I

which is isolated as the base or a pharmaceutically acceptable salt thereof.

2. The method of Claim 1 wherein the conversion the 5-formyl compound of Formula V to citalopram is carried out by conversion of the formyl group by reaction with a reagent R³-X-NH₂, wherein R³ is hydrogen, lower alkyl, aryl or heteroaryl and X is O, N or S, followed by dehydration with a dehydration agent.

10

3. The method of Claim 1 or 2 wherein R is a group

4. The method of Claim 3 wherein R¹ and R² are lower alkyl or R¹ and R² are linked and together designate a 4- or 5-membered chain optionally comprising an S, O or N atom.

15

5. The method of Claim 4 wherein R¹ and R² are both methyl or R¹ and R² together with the N-atom to which they are linked form a morpholinyl group.


6. The method of Claim 1 or 2 wherein R is an optionally substituted 4,5-dihydro-1,3-oxazol-2-yl group

20

7. The method of Claim 6 wherein R is 4,5-dihydro-4,4-dimethyl-1,3-oxazol-2-yl.

8. The method of any of Claims 1 - 7 characterized in that the intermediate of Formula IV is prepared by ring closure of the corresponding compound of Formula VI:

25




Formula VI.

Wherein R is as defined in Claim 1.


9. The method of Claim 8 characterized in that the compound of Formula VI is obtained from the corresponding 5-substituted phthalide derivative by two successive Grignard reactions, i.e. with a Grignard reagent of 4-halogen-fluorophenyl and a Grignard reagent of 3-halogen-N,N-dimethyl-propylamine, respectively.
10. The method of Claim 6 and 8 characterized in that the compound of Formula VI is prepared from 4-dimethylamino-1-(4-fluorophenyl)-butan-1-one by Grignard reaction with a properly protected 2-(hydroxymethyl)-4-(1,3-oxazol-2-yl)-phenyl magnesium halogenide derivative.
11. The method of Claim 8-10 wherein the ring closure of the compound of Formula VI is effected by acidic ring closure performed by an inorganic acid, such as a sulfuric or phosphoric acid, or an organic acid, such as methanesulfonyl, p-toluenesulfonyl or trifluoroacetic acid.
12. The method of any of Claims 8-10 wherein the ring closure of the compound of Formula VI is performed by a basic ring closure via a labile ester preferably with simultaneous esterification and addition of base.
13. The method of Claim 12 wherein the labile ester is the methane sulfonyl, p-toluene sulfonyl, 10-camphorsulfonyl, trifluoroacetyl or trifluoromethanesulfonyl ester and the base is triethyl amine, dimethylaniline or pyridine.
14. The method of any of Claims 11 - 13 wherein, before further reaction, the intermediate of Formula VI is separated into its enantiomers, thereby obtaining the enantiomer giving S-citalopram.

15. An intermediate for preparation of citalopram having the Formula IV



Formula V.

- 5 16. An intermediate for preparation of citalopram having the Formula VI



Formula IV

wherein is as defined in Claim 1.

10

17. An antidepressant pharmaceutical composition comprising citalopram manufactured by the process of any of Claims 1 - 14.

18. Use of an intermediate of Claim 15 for the preparation of citalopram.

15

19. Use of an intermediate of Claim 16 for the preparation of citalopram.